Navigation Links
Wyeth Provides Regulatory Update on Prevnar 13* in the United States
Date:8/11/2009

sion of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, clinical trial data are subject to differing interpretations, and the views of regulatory agencies, medical and scientific experts and others may differ from ours. There can be no assurance that Prevnar 13 will receive regulatory approval in the United States or in other markets or will be commercially successful. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and exp
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
2. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
3. Wyeth Announces Holder Right to Surrender Convertible Debentures
4. Wyeth Declares Common Stock Dividend
5. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
6. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
7. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
8. Wyeth Declares Common and Preferred Stock Dividends
9. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
10. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
11. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
(Date:9/18/2014)... Research and Markets has announced ... Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & ... The global companion diagnostics market is expected ... to 2019. Factors such as rising need for personalized ... by the pharmaceutical industry, support from regulatory authorities, and ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Thought leaders from around the world converge on ... Biomedical, Inc., a,medical technology company that markets the ... a Scientific Advisory Board. The,Board,s purpose is to ... of Provant, new product development, and further,application of ...
... DOYLESTOWN, Pa., May 20 Recognizing National,Hepatitis B Awareness ... Foundation,and the Association of Asian Pacific Community Health Organizations,(AAPCHO) ... the Health Needs of Women and Children," on May ... Honda (CA) and Charles Dent (PA). It,will call urgent ...
... CALGARY, May 20 /PRNewswire-FirstCall/ - Oncolytics Biotech ... that it has been granted,U.S. Patent 7,374,752 ... Disorders." The claims cover pharmaceutical compositions,which comprise ... the Company with additional patent protection for,reovirus ...
Cached Biology Technology:Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 2Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts 3Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on 'Zero Tolerance for Hepatitis B' 2Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent 2
(Date:9/18/2014)... of camouflage: you don,t just blend in, the background ... uncommon as you might think. Kathryn Feller, from the ... larval life stages of many marine species are transparent. ... most creatures cannot make transparent. Feller explains that the ... eye unit with an opaque pigment to prevent light ...
(Date:9/17/2014)... the Arts and Humanities has received a $260,000 grant ... project, "The Boundaries of the Human in the Age ... a wide-ranging series of events aimed at exploring two ... artists and researchers who are exploring the boundaries of ... humanism, and the other involves the increasingly influential hypothesis ...
(Date:9/17/2014)... and their environmental impact recently scored a major win. ... on the bags, and Governor Jerry Brown is expected ... not yielding without a fight, according to an article ... newsmagazine of the American Chemical Society. , Alexander Tullo, ... campaign logged its first small victory in 1990 when ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Mellon Foundation awards grant for major project in the humanities and sciences 2
... (SACRAMENTO, Calif.) A new UC Davis study has found ... those who earn higher wages, adding to growing evidence that ... "Our study clarifies a link that has been assumed but ... study and professor in the UC Davis Center for Healthcare ...
... of a collaborative grant from the Samuel Waxman Cancer ... designed to kill non-Hodgkin lymphoma tumor cells. The breakthrough ... The Foundation-funded investigators include Ari Melnick, M.D., of Weill ... of Maryland and Gilbert Priv, Ph.D., of the University ...
...   , ... PRINCETON, N.J. , May 10 ... R&D services, announced today that it has created a new Discovery & ... immunology services, Biomarker Center of Excellence, and Genomics Laboratory. Leveraging its minority ...
Cached Biology News:UC Davis study links obesity with lowest earnings 2Scientists design new drug type to kill lymphoma cells 2Covance Establishes New Discovery & Translational Services Group 2Covance Establishes New Discovery & Translational Services Group 3
... mm Culture Dishes BD BioCoat Collagen I ... a uniform application of rat tail collagen type ... ,Surface : ECM/attachment factors ,Surface ... : 60 mm x 15 mm ...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Biology Products: